CPIX - Cumberland Pharmaceuticals Inc Debt to Book Capitalization Ratio

Graphic logo of Cumberland Pharmaceuticals Inc (CPIX)

The historical debt-to-book capitalization trend demonstrates the evolution of the credit load for Cumberland Pharmaceuticals (CPIX) amid the saturation of the US antidote market. The value 0.28 reflects the most recent metric reading. The financial model relies on sales of the hospital drugs Acetadote and Caldolor. Ownership of niche emergency care products provides the company with high resilience to market shocks.

CPIX (Cumberland Corp) Debt to Book Value history from 07/04/2022 to 10/28/2026
Core merchandise of Cumberland Pharma

Analyzing the debt load of Cumberland Pharmaceuticals (CPIX) relative to its balance sheet capital allows for an assessment of the company's financial stability. This ratio compares the issuer's total liabilities to its net assets. An increase in this metric signals insolvency risks, whereas a minimum value may indicate an inefficient use of leverage. Stable demand for hospital drugs ensures a predictable cash flow, enabling Cumberland Pharmaceuticals (CPIX) to safely service its debt while maintaining high profitability.

Competitors of Cumberland Pharmaceuticals

Debts to Book Capitalization HLN (Haleon plc)|kenvue.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Verona Pharma (VRNA)|MENS: Debt to Net Assets Ratio|LGND (Ligand Pharma) - Debt to Book Capitalization Ratio|Amneal Corp (AMRX) - Debt to Book Value|PRGO (Perrigo Company plc) - Debts to Book Capitalization|Debts to Book Capitalization alvotech.com (ALVO)|Liquidia (LQDA) - Debt to Book Value|Debt to Net Assets Ratio GLPG (Galapagos N.V.)|ANIP: Debt to Book Capitalization Ratio|MNKD - Debts to Book Value|Debt to Book Value Amphastar Pharmaceuticals AMPH|PCRX - Debt to Book Capital|Debts to Book Capitalization ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Debt to Net Assets Ratio|Debts to Book Capitalization AQST (Aquestive Pharma)|Debts to Book Value SCPH|Tectonic Therapeutic, Inc. (TECX) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio tonixpharma.com (TNXP)|China SXT Pharmaceuticals, Inc. - Debts to Book Capitalization|EPRX - Debt to Book Value|BioHarvest - Debt to Book Value|EXOZ: Debts to Book Capitalization|ORMP (oramed.com) - Debt to Book Capitalization Ratio|Entera Bio (ENTX) - Debt to Book Value|Debts to Book Capitalization MindWalk Holdings Inc.|Debt to Book Capitalization Ratio ABVC BioPharma Inc.|Quantum BioPharma Limited - Debts to Book Capitalization|Debts to Book Value FGEN (FibroGen Corporation)|Debt to Book Capitalization Ratio Telomir Pharmaceuticals|Rani Therapeutics Holdings - Debt to Net Assets Ratio|SNYR - Debt to Book Capitalization Ratio|RLYB - Debt to Book Capitalization Ratio|LEXX: Debts to Book Capitalization|PULM (Pulmatrix Corporation) - Debts to Book Capitalization|Debt to Book Capitalization Ratio Pheton Holdings Limited (PTHL)|Debt to Book Value Ratio Aptorum|Debts to Book Capitalization Lyra Therapeutics LYRA|Debt to Book Value Ratio Impact BioMedical, Inc. IBO|Debt to Book Value TNF Pharmaceuticals, Inc.|cbdMD Inc. - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio PainReform Ltd.|CYTO - Debts to Book Capitalization Ratio|Debts to Book Capitalization Lipella Pharmaceuticals, Inc. LIPO|OptiNose Inc (OPTN) - Debt to Net Assets Ratio|PIRS (Pieris) - Debts to Book Capitalization|Debts to Book Capitalization PROC|Petros Pharmaceuticals (PTPI) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio QLI (qlsyy.net)|ACELYRIN - Debt to Book Capitalization Ratio|Debt to Book Value TFF Pharmaceuticals Inc. TFFP